A feasibility trial to examine the use of guided self-help for Huntington’s disease gene expansion carriers with anxiety

Not Applicable

• Conditions: Anxiety among Huntington's disease gene expansion carriers; Mental and Behavioural Disorders

• Registration Number: ISRCTN47330596
• Lead Sponsor: eicestershire Partnership NHS Trust

Brief Summary

2023 Protocol article in https://pubmed.ncbi.nlm.nih.gov/37700320/ (added 14/09/2023)

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2022-09-28
• Last Update Posted: 16 October 2023
• Study Completion: 2024-09-30

Recruitment & Eligibility

• Status: Ongoing
• Sex: All
• Target Recruitment: 36

Inclusion Criteria

Huntington's Disease Participants
1. Confirmed genetic test for HD (CAG >=36)
2. Diagnosed with clinical anxiety using Structured Clinical Interview for DSM-5 (SCID-5)
3. Premanifest or manifest HD
4. For those who are manifest HD, will be early-stage HD as defined as those with a United Huntington’s Disease Rating Scale (UHDRS) Total Functional Capacity (TFC) score of 9-13
4. If taking a medication known to impact on anxiety, must be stabilised for 4 weeks
5. Able to read/understand English
6. Aged >=18 years
7. Able and willing to give informed consent

HD Carers
1. Aged >=18 years
2. Had some involvement in the intervention
3. Able to give informed consent

Exclusion Criteria

HD Participants
1. Current suicidal intent
2. Significant cognitive or communication impairment as determined by MOCA and clinical psychologist opinion
3. Unstable medical conditions
4. Currently receiving another psychological intervention aimed at reducing anxiety
5. Acute psychosis or other acute psychiatric presentation requiring intense/urgent input from mental health professionals

Study & Design

• Study Type: Interventional
• Study Design: Not specified